← Human Trials & Peer-Reviewed Studies
Evaluation of two health status measures in adults with growth hormone deficiency.
Plain-language guide to PMID 12641626 (2003): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 157 patients.
Key Facts
- PMID
- 12641626
- Journal
- Clinical endocrinology
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- McMillan CV et al. (5 authors)
- DOI
- 10.1046/j.1365-2265.2003.01736.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
To evaluate the psychometric properties of two health status measures for adults with growth hormone deficiency (GHD): Nottingham Health Profile (NHP) and Short-Form Health Survey (SF-36).
(1) A cross-sectional survey of adults with treated or untreated GHD to assess reliability and validity of the questionnaires.
(2) A randomized, placebo-controlled study of 3 months' GH withdrawal from GH-treated adults to assess the sensitivity of the questionnaires to change.
Who Took Part
The abstract describes 157 patients taking part.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
(2) GH treatment was withdrawn from 12 of 21 GH-treated adults, all with severe GHD (peak GH < 7.7 mU/l on provocative testing), mean age 44.9 years (range 25-68 years).
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
What Was Measured
Topics PubMed links to this paper include Cross-Sectional Studies, Growth Hormone, Health Status Indicators, Hormone Replacement Therapy, Reproducibility of Results, Sensitivity and Specificity and Statistics, Nonparametric.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 157 patients.
The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2003 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.